Amryt Pharma plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amryt Pharma plc
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.
Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Aegerion Pharmaceuticals, Inc.
- Amryt Pharma Holdings Limited
- Birken GmbH
- Birken AG
- Chiasma, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.